InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

- Current share price for LTP : $0.435

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$79 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2026 8:22AM $0.440 $0.435 fallen by 1.14%
$79 Results of Meeting 23 Oct 2026 5:04PM $0.445 $0.435 fallen by 2.25%
$79 AGM Presentation 23 Oct 2026 2:00PM $0.460 $0.435 fallen by 5.43%
$79 SPONTAN to be Evaluated in Pulmonary Arterial Hypertension 22 Oct 2026 8:24AM $0.485 $0.435 fallen by 10.31%
$79 SPONTAN passes 2,000 dispensed units in Australia 21 Oct 2026 8:44AM $0.470 $0.435 fallen by 7.45%
$79 Investor Webinar Presentation 6 Oct 2026 8:39AM $0.495 $0.435 fallen by 12.12%
$79 First ROXUS Prescriptions Fulfilled in the United States 6 Oct 2026 8:30AM $0.495 $0.435 fallen by 12.12%
$79 Clinical and Commercial Update - Investor Webinar 2 Oct 2026 10:22AM $0.475 $0.435 fallen by 8.42%
$79 SPONTAN Phase II Final Results 1 Oct 2026 8:24AM $0.480 $0.435 fallen by 9.38%
$79 Notice of Annual General Meeting/Proxy Form 22 Sep 2026 4:13PM $0.470 $0.435 fallen by 7.45%
$79 Application for quotation of securities - LTP 11 Sep 2026 2:49PM $0.455 $0.435 fallen by 4.40%
$79 Application for quotation of securities - LTP 4 Sep 2026 3:58PM $0.540 $0.435 fallen by 19.44%
$79 Investor Presentation 3 Sep 2026 8:32AM $0.488 $0.435 fallen by 10.77%
$79 LTR Expands Men's Health Portfolio with KYZATREX Pilot 1 Sep 2026 8:15AM $0.505 $0.435 fallen by 13.86%
$79 FY26 Results Announcement 28 Aug 2026 7:48AM $0.480 $0.435 fallen by 9.38%
$79 Appendix 4G and Corporate Governance Statement 28 Aug 2026 7:48AM $0.480 $0.435 fallen by 9.38%
$79 Appendix 4E and Annual Report to Shareholders 28 Aug 2026 7:48AM $0.480 $0.435 fallen by 9.38%
$79 SPONTAN Real-World Study Reports 93% Response 11 Aug 2026 8:32AM $0.470 $0.435 fallen by 7.45%
$79 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jul 2026 9:01AM $0.510 $0.435 fallen by 14.71%
$79 LTR Executes U.S. Commercial Agreement with Strive 20 Jul 2026 8:55AM $0.510 $0.435 fallen by 14.71%
$79 LTR Executes Definitive U.S. Commercial Agreement with Shed 17 Jul 2026 8:48AM $0.495 $0.435 fallen by 12.12%
$79 Notification regarding unquoted securities - LTP 10 Jul 2026 4:28PM $0.520 $0.435 fallen by 16.35%
$79 OROFLOW Clinical Study Receives Ethics Approval 24 Jun 2026 8:22AM $0.565 $0.435 fallen by 23.01%
$79 Response to ASX Aware Letter 15 Jun 2026 2:16PM $0.505 $0.435 fallen by 13.86%
$79 LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS 11 Jun 2026 8:38AM $0.425 $0.435 risen by 2.35%

1 - 25 of 157 results

Page 1 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.